Literature DB >> 25877932

VIP boosts regulatory T cell induction by trophoblast cells in an in vitro model of trophoblast-maternal leukocyte interaction.

Laura Fraccaroli1, Esteban Grasso1, Vanesa Hauk1, Daniel Paparini1, Elizabeth Soczewski1, Gil Mor1, Claudia Pérez Leirós1, Rosanna Ramhorst2.   

Abstract

Inducible regulatory T cells (Tregs) exert a timely and efficient immunosuppressive action at the critical peri-implantation stage essential for maternal tolerance to the conceptus. Vasoactive intestinal peptide (VIP) promotes anti-inflammatory and tolerogenic profiles through binding to VIP receptors on immune cells. We evaluated whether VIP produced by trophoblast cells induces Tregs during the early interaction of maternal leukocytes with trophoblast cells, thus contributing to maternal tolerance. We used an in vitro model of maternal leukocyte-trophoblast cell interaction represented by cocultures of fertile women's PBMCs with a human trophoblast cell line (Swan-71) and evaluated the effect of VIP added exogenously and of the endogenous polypeptide. VIP increased the frequency of CD4(+)CD25(+)FoxP3(+) cells after coculture, and these cells were able to suppress the maternal alloresponse. VIP also increased the frequency of CD4(+)IL10(+) and CD4(+)TGFβ(+) cells, but it did not modulate IFN-γ or IL-17 production. Swan-71 secreted VIP, and their coculture with maternal PBMCs significantly increased the frequency of Tregs. This effect was even more pronounced if the trophoblast cells had been pretreated with VIP. In both situations, the VIP antagonist prevented the increase in the frequency of CD4(+)Foxp3(+) cells, reflecting a specific effect of the polypeptide after the interaction with Swan-71 cells. Finally, the increase in CD4(+)CD25(+)FoxP3(+) frequency was prevented by an anti-TGF-β Ab and a VIP antagonist. These results suggest that VIP could have an active role in the immunoregulatory processes operating in the maternal-placental interface by contributing to the induction of Tregs through a mechanism involving TGF-β1. © Society for Leukocyte Biology.

Entities:  

Keywords:  TGF-β; early pregnancy; iTreg; tolerance

Mesh:

Substances:

Year:  2015        PMID: 25877932      PMCID: PMC6608015          DOI: 10.1189/jlb.1A1014-492RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   6.011


  56 in total

1.  Regulation of VIP production and secretion by murine lymphocytes.

Authors:  C Martinez; M Delgado; C Abad; R P Gomariz; D Ganea; J Leceta
Journal:  J Neuroimmunol       Date:  1999-01-01       Impact factor: 3.478

2.  Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease.

Authors:  M Delgado; C Abad; C Martinez; J Leceta; R P Gomariz
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

3.  Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response.

Authors:  Alejo Chorny; Elena Gonzalez-Rey; Amelia Fernandez-Martin; Doina Ganea; Mario Delgado
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

Review 4.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance.

Authors:  S Sakaguchi; N Sakaguchi; J Shimizu; S Yamazaki; T Sakihama; M Itoh; Y Kuniyasu; T Nomura; M Toda; T Takahashi
Journal:  Immunol Rev       Date:  2001-08       Impact factor: 12.988

5.  Pregnancy does not alter the response of uterine arteries to vasoactive intestinal polypeptide.

Authors:  S Jovanovic; L Grbovic; A Jovanovic
Journal:  Mol Hum Reprod       Date:  2000-04       Impact factor: 4.025

6.  Placental expression of substance P and vasoactive intestinal peptide: evidence for a local effect on hormone release.

Authors:  D Marzioni; G Fiore; A Giordano; M Nabissi; P Florio; F Verdenelli; F Petraglia; M Castellucci
Journal:  J Clin Endocrinol Metab       Date:  2004-12-28       Impact factor: 5.958

7.  Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model.

Authors:  Ana Claudia Zenclussen; Katrin Gerlof; Maria Laura Zenclussen; André Sollwedel; Annarosa Zambon Bertoja; Thomas Ritter; Katja Kotsch; Joachim Leber; Hans-Dieter Volk
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

8.  Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.

Authors:  M Delgado; E J Munoz-Elias; R P Gomariz; D Ganea
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

9.  Regulatory T cells mediate maternal tolerance to the fetus.

Authors:  Varuna R Aluvihare; Marinos Kallikourdis; Alexander G Betz
Journal:  Nat Immunol       Date:  2004-02-01       Impact factor: 25.606

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  8 in total

Review 1.  The role of neutrophil activation in determining the outcome of pregnancy and modulation by hormones and/or cytokines.

Authors:  S Hahn; P Hasler; L Vokalova; S V van Breda; O Lapaire; N G Than; I Hoesli; S W Rossi
Journal:  Clin Exp Immunol       Date:  2019-03-13       Impact factor: 4.330

2.  Vasoactive intestinal peptide shapes first-trimester placenta trophoblast, vascular, and immune cell cooperation.

Authors:  Daniel E Paparini; Ruhul H Choudhury; Daiana M Vota; Magdalena Karolczak-Bayatti; Sarah Finn-Sell; Esteban N Grasso; Vanesa C Hauk; Rosanna Ramhorst; Claudia Pérez Leirós; John D Aplin
Journal:  Br J Pharmacol       Date:  2019-03-18       Impact factor: 8.739

Review 3.  Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.

Authors:  Katherine E Olson; Howard E Gendelman
Journal:  Curr Opin Pharmacol       Date:  2015-11-11       Impact factor: 5.547

4.  Activation of VIP signaling enhances immunosuppressive effect of MDSCs on CMV-induced adaptive immunity.

Authors:  Parvin Forghani; Christopher T Petersen; Edmund K Waller
Journal:  Oncotarget       Date:  2017-09-07

5.  Vasoactive Intestinal Peptide induces glucose and neutral amino acid uptake through mTOR signalling in human cytotrophoblast cells.

Authors:  Fatima Merech; Elizabeth Soczewski; Vanesa Hauk; Daniel Paparini; Rosanna Ramhorst; Daiana Vota; Claudia Pérez Leirós
Journal:  Sci Rep       Date:  2019-11-20       Impact factor: 4.379

6.  Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice.

Authors:  Katherine E Olson; Lisa M Kosloski-Bilek; Kristi M Anderson; Breha J Diggs; Barbara E Clark; John M Gledhill; Scott J Shandler; R Lee Mosley; Howard E Gendelman
Journal:  J Neurosci       Date:  2015-12-16       Impact factor: 6.167

7.  Vasoactive Intestinal Peptide modulates trophoblast-derived cell line function and interaction with phagocytic cells through autocrine pathways.

Authors:  Daiana Vota; Daniel Paparini; Vanesa Hauk; Ayelén Toro; Fatima Merech; Cecilia Varone; Rosanna Ramhorst; Claudia Pérez Leirós
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

8.  VIP Promotes Recruitment of Tregs to the Uterine-Placental Interface During the Peri-Implantation Period to Sustain a Tolerogenic Microenvironment.

Authors:  Lucila Gallino; Vanesa Hauk; Laura Fernández; Elizabeth Soczewski; Soledad Gori; Esteban Grasso; Guillermina Calo; Nora Saraco; Esperanza Berensztein; James A Waschek; Claudia Pérez Leirós; Rosanna Ramhorst
Journal:  Front Immunol       Date:  2020-01-08       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.